Special Issue "Supportive and Palliative Cancer Treatment"

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: 30 November 2020.

Special Issue Editor

Prof. Gil Bar-Sela
Guest Editor
Oncology and Hematology Division, Emek Medical Center, Afula
Interests: palliative care; complementary medicine; cannabis research; immunotherapy; skin cancers; sarcoma

Special Issue Information

Dear Colleagues,

Modern medicine has brought about an increase in the life expectancy of a significant number of patients with advanced cancer. Almost all international oncology groups recommend that combined standard oncology care and palliative care should be considered early in the course of the illness for any patient with metastatic cancer and/or a high symptom burden. However, a gap exists between this recommendation and current practice.

Supportive care is mainly related to improving quality of life during oncology treatments, including surgery, radiotherapy, and adjuvant chemo- or immunotherapy. Taken together, supportive and palliative care, with its focus on management of symptoms care, psychosocial support, and assistance with decision-making, has the potential to improve quality of life, prolong survival, and reduce use of medical services.

The journal Pharmaceuticals invites both reviews and original articles that shed light on the challenges and opportunities of using different drugs, natural products, and a specific nutritional diet for symptom control and reducing oncology treatment side effects in cancer patients. Basic studies that provide hints for future applications in supportive oncology care are also welcome. The collection of manuscripts will be published as a Special Issue of the journal.

Prof. Gil Bar-Sela
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • cancer
  • palliative care
  • supportive care
  • oncology
  • complementary medicine
  • cannabis
  • oncology

Related Special Issues

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Open AccessArticle
Wheatgrass Juice Administration and Immune Measures during Adjuvant Chemotherapy in Colon Cancer Patients: Preliminary Results
Pharmaceuticals 2020, 13(6), 129; https://doi.org/10.3390/ph13060129 - 23 Jun 2020
Adjuvant chemotherapy is recommended in high-risk stage II–III colorectal cancer (CC). We examine the effect of daily wheatgrass juice (WGJ) intake in addition to chemotherapy on immune parameters, including IL-6, IL-8, IL-10, IL-12, and white blood cells (WBCs) among CC patients. In a [...] Read more.
Adjuvant chemotherapy is recommended in high-risk stage II–III colorectal cancer (CC). We examine the effect of daily wheatgrass juice (WGJ) intake in addition to chemotherapy on immune parameters, including IL-6, IL-8, IL-10, IL-12, and white blood cells (WBCs) among CC patients. In a controlled prospective trial, 100 stage II–III CC patients were enrolled. According to patient preference, they were divided into two subgroups, control group and intervention group, 50 patients each, all of whom received the same standard postoperative adjuvant chemotherapy, plus consumption of 60 cc WGJ daily in the intervention group. Blood samples were collected at baseline (T0) and upon treatment termination, 5–6 months later (T1). Cytokine concentrations were assessed using ELISA kits. Anti-inflammatory cytokine IL-10 concentrations were significantly higher in the WGJ group than in the control group at T1. The decline in WBC counts between T0 and T1 was significantly lower in the WGJ group. No significant differences were observed in IL-6, IL-8, and IL-12 concentrations between the study groups. The higher levels of IL-10 and the attenuating of WBC decline during chemotherapy may constitute preliminary evidence of the beneficial effects of WGJ on immune parameters, when given as a supplement to standard care. In light of these preliminary results, WGJ supports immunological parameters during adjuvant chemotherapy. Nevertheless, future studies are needed in order to translate those results to clinical recommendations for cancer survivors. Full article
(This article belongs to the Special Issue Supportive and Palliative Cancer Treatment)
Show Figures

Graphical abstract

Back to TopTop